Safety Evaluation of Adverse Reactions in Diabetes
NCT02092597 on ClinicalTrials.gov · last registry update 2018-02-07
Finished October 2015, after enrolling 42 people. Primary outcome, as filed: Heart rate. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Charles University, Czech Republic
- Sponsor type
- Other
- Enrollment
- 42
- Started
- 2013-10
- Primary completion
- 2015-10 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Heart rate
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.